Navigation Links
Biotech Executive Salaries Continue to Rise Despite Weak Economy
Date:9/19/2012

ATLANTA, Sept. 19, 2012 /PRNewswire-USNewswire/ -- Amgen CEO Kevin Sharer, at $1.75 million in his final year before retirement, led the list of highest-salaried biotechnology executives in 2011, followed by John Martin, Gilead Sciences CEO, with $1.42 million, although Martin topped all executives in total compensation, with $54.58 million, to lead the "Millionaire's Club," according to data in the BioWorld Executive Compensation Report 2013: Trends in C-Level Salaries and Benefits in the Biopharma Market (ECR). 

(Logo: http://photos.prnewswire.com/prnh/20120628/DC32901LOGO)

Rounding out the top of the list of the highest-salaried U.S. biotech executives is George Scangos, Biogen Idec CEO, at $1.24 million, followed by Matthew Emmens, Vertex Pharmaceuticals, with $1.16 million.

It's still predominately a men's club, but women made noteworthy progress on some of the lists. Adelene Perkins, Infinity Pharmaceuticals CEO, at $820,000, came in at number 53 on the list of the top 167 CEOs, ranked by total annual compensation, to head a list of five female CEOs making the roll.

"In recent years, the biotech market has attained overall profitability, achieved its highest-ever market value and increased the number of annual product approvals; these are the executive decision-makers guiding the industry through the most profitable and productive period in its history, but also in what is, arguably, its most tenuous economic period," said Michael Harris, BioWorld's ECR senior editor.

Data on biotech corporate officers at companies outside the U.S. was included for the first time in ECR 2013 and the list shows only one executive, Peer Schatz, Qiagen CEO, at $1.31 million, earning more than $1 million.

"Negotiations for executive compensation packages can be better managed when there is comparative data on competitive-level positions," Harris said. "The compensation trends in BioWorld's ECR reveal that dynamics such as the recession, inherent volatility associated with drugmaking and the overwhelming risk of failure seem to have invoked the companies to double down on their efforts to rely on – and pay for – the best leadership."

Data in the 2013 ECR covers 798 C-level executives representing 258 companies in the U.S., with additional sections covering 87 executives representing 55 non-U.S. companies in Europe and Canada.

BioWorld is the biopharmaceutical industry's most respected news source for more than two decades. For a copy of the ECR, call (800) 477-6307 or, outside the U.S., (404) 262-5476 or visit www.bioworld.com.

CONTACT: Lynn Yoffee, Executive Editor, +1-404-262-5408

Web Site: http://www.bioworld.com


'/>"/>
SOURCE BioWorld
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
4. Germany Prioritizes Medical Biotechnology with New Initiatives
5. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
6. Why Texas is #1 in Business: Local BioTech Company Expands
7. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory
8. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
9. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
10. Biomass characterization technology research highlighted in Industrial Biotechnology journal
11. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):